Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CRISPR/Cas9 genome-edited universal CAR T cells in patients with relapsed/refractory lymphoma

10 Jan 2022

Abstract excerpt

Chimeric antigen receptor (CAR)-modified T cells have been reported to successfully treat patients with hematological malignancies. 4]

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Viral Infectious Diseases and Gene Expression in Insects
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35008103
DOI: 10.1182/bloodadvances.2021006232

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CRISPR/Cas9 genome-edited universal CAR T cells in patients with relapsed/refractory lymphomaPMID 35008103Read ↗

Strengthening the CAR-T Cell Therapeutic Application using CRISPR/Cas9 TechnologySemantic proximity Read ↗

Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapySemantic proximity Read ↗

Applications and explorations of CRISPR/Cas9 in CAR T-cell therapySemantic proximity Read ↗

Strengthening the CAR‐T cell therapeutic application using CRISPR/Cas9 technologySemantic proximity Read ↗

CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapySemantic proximity Read ↗

CRISPR-Cas9-mediated multiplex gene editing in CAR-T cellsSemantic proximity Read ↗

Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome EditingSemantic proximity Read ↗

Boosting CAR-T cell therapy with CRISPR technologySemantic proximity Read ↗

Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapySemantic proximity Read ↗

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editingSemantic proximity Read ↗

CRISPR/Cas-mediated non-viral genome specific targeted CAR T cells achieve high safety and efficacy in relapsed/refractory B-cell non-Hodgkin lymphomaSemantic proximity Read ↗

CAR-T Therapy and CRISPR/Cas9 in Cancer TreatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.